The ECPAS Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ECPAS gene, which encodes the Ecm29 scaffold protein. This loss-of-function model enables the study of Ecm29-dependent processes without the variables associated with clonal selection. By using a polyclonal population, researchers can assess heterogeneous knockout effects that more closely mimic complex biological systems, making it suitable for quantitative and high-throughput applications in proteasome research.
The host cell line, HeLa, is an immortalized human cervical adenocarcinoma cell line that is HPV-18 positive and widely employed in biomedical research due to its robust growth, high transfectability, and well-characterized epithelial phenotype. HeLa cells provide a reproducible and experimentally tractable system for examining intracellular protein trafficking and the ubiquitin-proteasome system. Their cancerous origin also makes them particularly relevant for studying proteasome regulation in tumor biology.
ECPAS (Ecm29) functions as a molecular scaffold that physically links the 26S proteasome to the dynein-dynactin motor complex, thereby enabling microtubule-dependent transport and subcellular localization of proteasomes. This interaction is critical for proteasome distribution in response to cellular stress. Ecm29 also stabilizes the 26S proteasome holoenzyme by interacting with the 19S regulatory particle, and it may regulate proteasome disassembly under proteotoxic conditions. Upstream, Ecm29 is phosphorylated by casein kinase 2 (CK2) and its association with the proteasome is influenced by mTOR signaling and proteasome inhibition. Downstream, disruption of Ecm29 impairs proteasome stability, reduces processive proteasomal degradation, and alters microtubule-associated trafficking. Representative pathway components include ubiquitin, the 26S proteasome, dynein, microtubules, and proteasome assembly chaperones.
In the HeLa cellular context, knockout of ECPAS disrupts the normal transport and localization of proteasomes, leading to altered degradation of key regulatory proteins and potentially affecting cell cycle progression and stress response pathways. Given the role of proteasome dysfunction in cancer, this model provides a platform to investigate how impaired proteasome trafficking contributes to tumor cell survival and sensitivity to proteasome inhibitors such as bortezomib. Additionally, because HeLa cells are HPV-driven, this system may offer insights into viral manipulation of host protein quality control.
Typical research applications include live-cell imaging of fluorescently tagged proteasomes to assess trafficking dynamics, co-immunoprecipitation assays to examine Ecm29-proteasome interactions, and in vitro proteasome activity assays to quantify catalytic function. This knockout model is also valuable for screening proteasome-modulating compounds and for exploring crosstalk between the ubiquitin-proteasome system and autophagy. Researchers can employ Western blotting for proteasome subunits and ubiquitin chain degradation assays to evaluate degradative capacity. The polyclonal nature supports pooled functional screens and robust statistical analyses. For detailed technical inquiries, please contact Ascent Research.
